Fate Therapeutics (FATE) Tops Q1 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.32), $0.07 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.63 million versus the consensus estimate of $876 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
• iShares Silver Trust (SLV) call put ratio 1.3 calls to 1 put as silver pulls back
• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c